12:20 PM EST - BELLUS Health Inc. : Announced that the U.S. Food and Drug Administration has accepted the Company's Investigational New Drug application, thus clearing the start of its Phase 2 study for BLU-5937 in chronic cough patients in the United States. BELLUS Health Inc.
shares T.BLU are trading unchanged at $1.65.
